SAN JOSE, Costa Rica – The tiny Latin American country that has become the region's second largest med-tech exporter behind Mexico is betting on disruptive technologies and trends to stay at the technological forefront. Costa Rica's med-tech exports have become one of the nation's most important sources of income and employment, and the country is focused on expanding the sector.

San Diego-based Tandem Diabetes Care Inc. reported financial results for the third quarter of 2019, with worldwide pump shipments soaring 112% to 17,839 pumps from 8,434 pumps in the same period a year ago. Revenue rose 105% to $94.7 million, up from $46.3 million in the third quarter of 2018.

The oncology field pioneered adaptive trial designs through efforts such as I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2), Puma Biotechnology Inc.’s phase II study of the pan-HER tyrosine kinase inhibitor neratinib (Nerlynx) as neoadjuvant therapy in metastatic breast cancer, and the ongoing multidrug, biomarker-driven non-small-cell lung cancer trial known as Lung-MAP.

Total raised in public, private and other financings of biotech companies, comparing 2019 vs. 2018.

Year-to-date money raised in public, private and other financings of biopharma companies.

Centogene BV filed to sell 4 million common shares on Nasdaq for between $14 and $16 in an IPO expected to raise $60 million at the midpoint.

“We’re in a global market. We need to stop being parochial and work globally from the beginning.”

The FDA’s Janet Woodcock, director of the Center for Drug Evaluation and Research, testified before a House subcommittee on the national security risk raised by U.S. reliance on China exports of active pharmaceutical ingredients (API).